To enroll, a woman must have metastatic, triple-negative breast cancer and be about to begin treatment with the chemotherapy drug cisplatin.
Ten women with advanced breast cancer will participate in one of the most intensive clinical trials ever conducted to identify molecular changes in individual tumors and to understand the strategies cancers adopt to escape chemotherapy. The study is seeking enrollees.
University of Washington scientists, along with colleagues from more than a half-dozen other institutions, are analyzing tumors’ genomic, transcriptomic, proteomic and metabolomic data – a so-called “panomic” approach. The study is called the "Intensive Trial of OMics in Cancer," or ITOMIC.
Read the full story at HSNewsBeat.